Novo Nordisk A/S

Alpha Score of 60 reflects moderate overall profile with weak momentum, strong value, moderate quality, moderate sentiment.

Novo Nordisk is a leading global pharmaceutical company headquartered in Denmark that specializes in developing and manufacturing medicines to treat serious chronic diseases. The company focuses on four primary therapeutic areas: diabetes, obesity, cardiovascular disease, and rare diseases including hemophilia and growth disorders. Its product portfolio includes diabetes treatments like Tresiba and Rybelsus, obesity medications such as Wegovy, cardiovascular and rare disease therapies, and hormone replacement treatments. Novo Nordisk operates manufacturing facilities across multiple continents and maintains research and development centers worldwide, serving millions of patients globally. The company is backed by the Novo Nordisk Foundation, one of the world's largest philanthropies, which influences its approach to healthcare innovation and patient access. Founded on principles emphasizing scientific excellence and compassion, Novo Nordisk combines breakthrough pharmaceutical research with a commitment to expanding medicine accessibility and working toward disease prevention and cure.